Results for this period
Third quarter1 January 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue was generated from product sales of Sancuso and episil, as well as Sancuso installment contract fee revenue and milestone revenue from episil, while product sales remain at an early stage and upfront investments in drug development exceeding product sales profit continue.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | ¥346 million (YoY +277.3%) |
| Operating profit | ¥-676 million |
| Ordinary income | ¥-680 million |
| Profit attributable to owners of the parent | ¥-680 million |
| Net income per share | -¥2.51 |
| Equity ratio | End of the current fiscal period 86.2 / End of previous period 81.7 |
| Total assets | ¥1,560 million |
| Net assets | ¥1,345 million |
| Cash flows from operating activities | ¥-576 million |
| Cash flows from investing activities | ¥-34 million |
| Cash flows from financing activities | ¥233 million |
| Cash and cash equivalents at end of period | ¥1,023 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Consolidated earnings forecasts have not been provided because it is difficult to make a reasonable earnings forecast. |
| Revision to Earnings Forecast | Revenue from product sales, etc. ¥420 million → ¥350 million（-16.7%） / Consolidated Earnings Forecast Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥27 million |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | 0 additions, 0 exclusions (no material changes) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 273,414,365 shares |
| Treasury Shares at Period-End | 409,143 shares |
| Factors Behind Changes in Business Performance | Revenue was generated from product sales of Sancuso and episil, as well as Sancuso installment contract fee revenue and milestone revenue from episil, while product sales remain at an early stage and upfront investments in drug development exceeding product sales profit continue. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was due to revenue from product sales of Sancuso and episil, as well as Sancuso installment contract fee revenue and milestone revenue from episil. At the same time, the company explained that product sales remain at an early stage and that it continues to make upfront investments in drug development exceeding product sales profit.